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Abstract
Background: “Neglected Tropical Diseases” (NTDs) affect millions of people in Africa, Asia and South America. The two
primary ways of strategic interventions are “preventive chemotherapy and transmission control” (PCT), and “innovative
and intensified disease management” (IDM). In the last 5 years, phenomenal progress has been achieved. However, it is
crucial to intensify research effort into NTDs, because of the emerging drug resistance. According to the World Health
Organization (WHO), the term NTDs covers 17 diseases, namely buruli ulcer, Chagas disease, dengue, dracunculiasis,
echinococcosis, trematodiasis, human African trypanosomiasis, leishmaniasis, leprosy, lymphatic filariasis, onchocerciasis,
rabies, schistosomiasis, soil-transmitted helminthes, taeniasis, trachoma, and yaws.
The aim of this study is to map out research and development (R&D) landscape through patent analysis of these identified
NTDs. To achieve this, analysis and evaluation have been conducted on patenting trends, current legal status
of patent families, priority countries by earliest priority years and their assignee types, technological fields of
patent families over time, and original and current patent assignees.
Main body: Patent families were extracted from Patseer, an international database of patents from over 100 patent
issuing authorities worldwide. Evaluation of the patents was carried out using the combination of different search terms
related to each identified NTD.
In this paper, a total number of 12,350 patent families were analyzed. The main countries with sources of inventions were
identified to be the United States (US) and China. The main technological fields covered by NTDs patent landscape are
pharmaceuticals, biotechnology, organic fine chemistry, analysis of biological materials, basic materials chemistry, and
medical technology. Governmental institutions and universities are the primary original assignees.
Among the NTDs, leishmaniasis, dengue, and rabies received the highest number of patent families, while human African
trypanosomiasis (sleeping sickness), taeniasis, and dracunciliasis received the least. The overall trend of patent
families shows an increase between 1985 and 2008, and followed by at least 6 years of stagnation.
Conclusion: The filing pattern of patent families analyzed undoubtedly reveals slow progress on research and
development of NTDs. Involving new players, such as non-governmental organizations may help to mitigate
and reduce the burden of NTDs.
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drug administration
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Background
In Africa, Asia and South America, a good number of
the population adds to the hundreds of millions of
people affected by “neglected tropical diseases” (NTDs).
According to the World Health Organization (WHO),
the term NTDs covers the following 17 diseases: buruli
ulcer, Chagas disease, dengue, dracunculiasis (guinea-
worm disease), echinococcosis, trematodiasis, human
African trypanosomiasis (sleeping sickness), leishmania-
sis, leprosy, lymphatic filariasis, onchocerciasis (river
blindness), rabies, schistosomiasis, soil-transmitted hel-
minthes, taeniasis, trachoma, and yaws [1]. Based on the
efforts of few researchers (e.g. Prof. Peter Hotez, Prof.
Alan Fenwick and Prof. Alan Fairlamb), the concept of
an umbrella category of these diverse diseases was estab-
lished in the aftermath of the Millennium Development
Goals (2000). In 2010, the WHO launched its first report
on NTDs defining the strategic approaches for reducing
the burden of NTDs [2]. Two years later, a “roadmap”
was published revealing the milestones set for 2015 and
2020. The “roadmap” specifies targets for the eradica-
tion, elimination and intensified control of identified
NTDs [3, 4].
For NTDs, the two primary methods of interventions
are “preventive chemotherapy and transmission control”
(PCT) covering “mass drug administraion” (MDA), and
“innovative and intensified disease management” (IDM).
In case of PCT, global strategies and applicable tools are
readily available [5]. The most important tool for control
is the administration of inexpensive (usually donated)
drugs to entire at-risk populations without prior individ-
ual diagnosis [6]. PCT allows the regular and coordi-
nated administration of single dose medicines on a large
scale for the treatment of dracunculiasis, leprosy, lymphatic
filariasis, onchocerciasis, schistosomiasis, soil-transmitted
helminthiases and trachoma. IDM focuses more on NTDs
for which simple tools and treatments are not yet available
in which wide scale prevention cannot be applied (eg. ef-
fective drug does not exist or the high risk population can-
not be reached) [7]. Some of the NTDs addressed by
itensified disease management include buruli ulcer, Chagas
disease, human African trypanosomiasis (sleeping sickness),
leishmaniasis and yaws (endemic treponematoses) [4].
The MDA program is part of the PCT, and it involves
regular drug donations. Several pharmaceutical companies,
such as Merck & Co., Pfizer, GlaxoSmith etc. have been
donating key drugs to address NTDs since the mid-1980s.
In the case of Merck & Co., there is a program to donate
Mectizan® indefinitely to support the fight of onchoceriasis
[8]. From a recent WHO report on “Unprecedented pro-
gress against NTDs”, 1 billion people have been treated for
at least one NTD in 2015 alone [9]. In spite of the success
of MDA programs, they are controversial and raise import-
ant issues for consideration, such as suboptimal coverage
or lack of efficacy [10]. Another concern about MDA pro-
grams is that they have been linked to drug and insecticide
resistance experienced in the veterinary field [11, 12]. In
fact, resistance to drugs has been detected in many para-
sites highlighting the risk of developing drug resistance
when a single drug is used and the drug pressure is high
[13]. Thus, drug donation cannot ameliorate the deficiency
of new chemical entities being researched and developed.
Taking on these challenges, the London Declaration (2012)
based on governments, charities, and pharmaceutical com-
panies aims to facilitate research and development (R&D)
beyond ensuring the necessary supply of drugs and other
interventions for NTDs for which treatments already exist.
Tables 1, 2 and 3 shows the global data on number of coun-
tries affected by NTDs, disease burden, major interventions
including information on prevention, treatment, drug
resistance and donation, and effectiveness of interventions.
According to the Global Burden of Disease 2015 study
[14], the overall disability-adjusted life-years (DALYs)
(an important parameter of disease burden) between
2005 and 2015, due to NTDs substantially declined. For
example, DALYs of human African trypanosomiasis, a
disease targeted for elimination has been reduced by
more than 70% since 2005. However, the epidemiological
improvement is not uniform. For example, both total
and age-standardised DALYs rates for dengue increased
by more than 50%.
The aim of this study is to determine the trends of
R&D on NTDs by performing a patent landscape ana-
lysis. Historically, patents encourage research by giving
monopoly to inventors over invention for 20 years and
disclosing these inventions for public use after this
period of time. To obtain a patent, an inventor must file
a patent application. A patent application does not auto-
matically give the applicant a temporary right against
infringement. A patent has to be granted for it to be
effective and enforceable against infringement. Perform-
ing a patent landscape analysis is an established method
for understanding R&D trends in the biomedical field.
This is because innovations stemming from biomedical
research possess a great potential for developments
which are often subjected to patent filings [15]. Add-
itionally, due to novel, user friendly data visualization
technologies and publicly accessible patent databases,
patent landscape analysis has become an available tool
for researchers and stakeholders to investigate emerging
areas and also to identify economically attractive
research gaps [16]. Considering the wide variety of contents
available in patents, they are essential source of information
for technological analysis [17, 18]. Although, technical pos-
sibilities for creating patent landscapes improved a lot in
the last years, today only a limited number of patent land-
scapes are addressing comprehensive questions on health
topics [19].
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This analysis addressed the patenting trends, current
legal status of patents, priority countries by earliest
priority years and their assignee types, technological
fields of patent families over time, and lastly, original
and current patent assignees in the last 30 years.
Methods
Patent families have been extracted from Patseer, an
international database of patents from over 100 patent
issuing authorities worldwide [20]. Evaluation of the pa-
tent families has been carried out using the combination
of different search terms related to each identified NTD.
The final set of keywords is presented in Additional file 1.
Keywords of each identified NTD (their synonyms and
truncation to cover different endings, singular/plural
etc.) have been obtained from the Medical Subject Head-
ings (MeSH) database of the National Library of Medi-
cine in which vocabulary thesaurus is used for indexing
articles for PubMed, fact sheets relating to NTDs pro-
duced by the WHO, and Google Scholar.
For visualization purposes of R&D trends, an add-
itional database and software, PatBase [21] was also
used; the patent collection retrieved from Patseer was
uploaded and analyzed in PatBase.
Technology domains and International Patent Codes
(IPC) have been adopted for topic identification for each
identified NTD. Technology domains are comprehensive
allocations of patented inventions. The first 4 digits of
IPC codes are linked with the 35 fields of technology, in
which categorization has been revised by the World In-
tellectual Property Organization [22]. The IPC catego-
rizes similar inventions thus, providing a single source
to browsing through all inventions relating to a specific
NTD using the titles, abstracts and claims of patent fam-
ilies have been accessed.
The analysis was based on simple patent families (a
group of one or more patent applications which repre-
sent the same invention) since patent applications are
often filed in more than one country. Duplicates have
been removed by creating simple families which repre-
sent the family members of a particular patent record
with same priority dates.
Legal status information is an important component
of patent information, as it determines whether
Fig. 1 Patenting trend by number of granted patent families and the total patent families. The overall filing trend in the last 30 years for NTDs reveals an
increasing trend between 1985 and 2014. Following the intense growing period between 1985 and 2008, there is no steady increase in the number of
total patent families, but there is a slow but continous growth in the number of granted patent families. Patent applications are not published until after
18 months, this explains why no data is presented after 2014
Fig. 2 Current legal status of patent families of NTDs. Almost 50% of the patents are not active. Record numbers refer to the number of
patent families
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examination of a patent application is still pending, or
the application was withdrawn or rejected, or a patent
has been granted and it is still valid or a granted patent
has expired, lapsed or been revoked due to an oppos-
ition. In PatSeer, setting “one member per family”
deduplication mode for an entered query, the displayed
record is represented by the legal status of its family
members. For example, if any one of the family mem-
bers has legal status as granted, the record displayed
will be marked as granted.
Results
In this study, the total number of patent families
reviewed was 12,350, out of which 3179 were granted
patent families. A distinction between research activities
for each NTD has been observed. Among the NTDs,
leishmaniasis, dengue, and rabies received the highest
number of families, while taeniasis and dracunciliasis the
least. The number of granted patent families and total
patent families for each NTD is presented in Table 1.
The overall patenting trend for NTDs is often character-
ized by the total number of simple families and granted
patent families (by year when it was granted). As pre-
sented in Fig. 1, there is a substantial increase in patent-
ing activities between 1985 and 2014 both in the total
numbers of patent families including applications and in
granted patent families. Although, total patenting activity
was fluctuating between 2003 and 2008 which was
followed by 6 years stagnation, mainly because of the de-
creasing number of applications. The increase in the
granted families is continuous but slow.
The variable trends in NTDs patenting can be classi-
fied into three distinguished catergories. The first cat-
egory shows an increasing trend in the number granted
patents based on patent families (buruli ulcer, Chagas
disease, dengue, onchocerciasis); the second category is
mostly characterized by stagnation (echinococcosis,
leishmaniosis, leprosy, rabies, schistosomiasis, trachoma,
Fig. 3 Number of granted patent families (a) and the total patent families (b) for the top five priority countries, by years. a: Main countries with source
of inventions are the United States and the European Union-European Patent Office. Record numbers refer to the number of granted patent families.
Priority countries are: US (United States), EP (European Union-European Patent Office), KR (Korea), JP (Japan), GB (Great Britain). b: Main countries with
source of inventions are the United States and China. Record numbers refer to the number of patent families. Priority countries are: US (United States),
CN (China), JP (Japan), EP (European Union-European Patent Office), GB (Great Britain)
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yaws); while the third category lacks a clear trend due to
the low number of filings (dracunculiasis, food-borne
trematodiasis, human African trypanosomiasis, lymph-
atic filariasis, soil-transmitted helminthes, taeniasis).
There was no significant increase in the number of
granted patent families for any of the NTDs in the last
10 years. The figures of annual patenting trends for each
NTD are presented in Additional file 2.
While the biphasic trends of IDM and PCT diseases
appear to be similar, the patenting trends of these
two groups reveal a slight noticable difference. In
comparison with the PCT group, the IDM group
show a more intense growth period and stagnation
after 2008 (see Additional file 2).
Patent applications are not published until after
18 months, so information after 2014 is not presented in
Fig. 1. Patents expire after 20 years. Legal status is import-
ant for information on commercial exploitability of patents.
Analysis of current legal status of the patent families of
NTDs, presented in Fig. 2, reveals that almost 50% of the
patents are non-active. This fact suggests that investing in
NTDs has a low commercial value. Among the 17 NTDs
identified, the prevalence of non-active patents is notice-
ably high in leprosy, schistosomiasis, trachoma and trema-
todiasis (see Additional file 2).
Analyzing the top priority countries (countries where ini-
tial patent filing was submitted) for the granted patent fam-
ilies, it was observed that the main priority countries are the
Fig. 4 Number of granted patent families (a) and the total patent families (b) for the top ten priority countries by types of assignee. a: Firm (firms), indiv
(individuals), univ. (universities), inst (non-profit institutions), govt (governments) and hosp (hospitals) are assignee types. “Others” classify the assignee
names or company names which do not fall under these categories (university, government, non-profit institution, hospital, individuals). Record numbers
referring to the number of granted patent families. Priority countries are: US (United States), EP (European Union-European Patent Office), KR (Korea), JP
(Japan), GB (Great Britain), RU (Russia), CN (China), FR (France), AU (Australia), IN (India). b: Firm (firms), indiv (individuals), univ. (universities), inst (non-profit
institutions), govt (governments) and hosp (hospitals) are assignee types. “Others” classify all the assignee names or company names which do not fall
under these categories (university, government, non-profit institution, hospital, individuals). Record numbers refer to the number of patent
families. Priority countries are: US (United States), CN (China), JP (Japan), EP (European Union-European Patent Office), GB (Great Britain),
FR (France), KR (Korea), DE (Germany), AU (Australia), RU (Russia)
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United States (US), European Union (EP), Korea (KR), Japan
(JP) and Great Britian (GB) in the last 30 years. However, by
focusing on the trend of total number of patent families, the
leading countries are the US, China (CN), JP, EP, and GB.
The gap between the first two priority countries is high, the
US and China are with 6154 and 2423 patent families re-
spectively. However, different patenting activity level of US
and China can be detected by ratio of applications for patent
families to granted patent families: 1898/3302 and 87/1525
respectively. With respect to NTDs, China appears as an
emerging priority country compared with the US since 2010
as presented in Fig. 3. This trend is observed particularly for
echinococcosis, rabies, schistosomiasis, and soil-transmitted
helminthes. For example, China has a set priority for the
soil-transmitted helminthiasis since 2010. Nonetheless, US
has kept its leading role in intensive research on NTDs, such
as leprosy, leishmaniasis and dengue. An interesting
exception is observed for trematodiasis, which has Russia as
its priority country.
In the US, firms hold a large percentage of patent fam-
ilies in comparison to other interest groups such as indi-
viduals, universities, governments, and institutes. In
China, France, Korea, and Russia, more than 50% of pat-
ents and applications were assigned to entities other
than firms. By focusing on the assignee types of granted
patent families, the role of firms is dominant, except for
France, Korea and Russia. In Korea, the universities, and
in Russia, no specified assignees are the major patent
holders. Distribution of assignee types among priority
countries is assessed in Fig. 4.
Figure 5 provides an overview of the identified NTDs
patent landscape in the form of technological fields. The
main technological subdomains are pharmaceuticals,
biotechnology, organic fine chemistry, analysis of
Fig. 5 Number of granted patent families (a) and the total patent families (b) for the technological subdomains over time. a: The main technological
subdomains are pharmaceuticals, biotechnology, organic fine chemistry, analysis of biological materials, basic materials chemistry and medical technology.
Contininous growth can be observed especially in the field of pharmaceuticals, biotechnology, organic fine chemistry. Record numbers refer to the number
of granted patent families. b: The main technological subdomains are pharmaceuticals, biotechnology, organic fine chemistry, analysis of biological materials,
basic materials chemistry and medical technology. Contininous growth can be observed especially in the field of pharmaceuticals, biotechnology, organic
fine chemistry between 1985 and 2011 followed by stagnations/slight decline. Record numbers referring to the number of patent families
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biological materials, basic materials chemistry and med-
ical technology. According to the NTDs trends, pharma-
ceuticals and biotechnology accounted for most patent
families filed in the last 30 years. These two fields have
shown substantial growth since 1985. Filings in organic
fine chemistry have dropped in the last 10 years. The
analysis of biological materials seems to be a popular
field of innovation. Patent families for basic materials
chemistry and medical technology have also shown sub-
stantial growth, in the overall analysis, but they account
for a small portion of the filings. Focusing on the
granted patent families, the stagnation/decline of the
pharmaceuticals, biotechnology, organic fine chemistry
fields are not yet present. The percentage of technical
subdomains (pharmaceuticals, biotechnology, organic
fine chemistry, analysis of biological materials, basic
materials chemistry and medical technology) for alive
versus non-alive patent families were similar. The high-
est proportions were observed in the pharmaceutical
field, and the high proportion of dead patent families in
the pharmaceutical is as a result of a decline in patent
applications. Additionally, by comparing the technical
subdomains of the IDM and PCT groups examined, it
was observed that they have the same subdomains rank-
ing order. However, while the hierarchy among subdo-
mains of IDM is rather constant, there are changes in
the positions of the subdomains of PCT. A very import-
ant observation is the clear decline in the number of pa-
tent families for pharmaceuticals and organic fine
chemistry in the group of PCT.
The IPC classification of NTDs patents showed that
class A61 is the most prominent class in which NTDs re-
search patents are being categorised. In respect of this
categorisation, A61K39/00 (medicinal preparations con-
taining antigens or antibodies) is the most dominant IPC
subgroup within the A61 class. Detailed research focus of
each disease is presented by IPC subgroups in
Additional file 2.
Fig. 6 Original and current patent assignees. For patent families of all NTDs, University of California and US Health are the major original assignees, and
Vertex Pharmaceuticals, Merck Sharp Incorporation are the main current assigness. Record numbers refer to the number of patent families
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For a patent landscape analysis, analyzing the distribution
of active patent applicants in a research field is important.
With respect to NTDs research, a lack of dominant as-
signees (more than 33% of patents) was observed (Fig. 6).
The main original assignees for NTDs research are govern-
mental institutions and universities, such as Univeristy of
California (US) or Pasteur Institute (FR). Among current as-
signees, firms such as Merck, Vertex Pharma Inc. tend to
take more financial risks on NTDs research.
Discussion
Long term trends reveal a continuous growth in the
number of patent families of NTDs with a slight
decrease after 2008. This continuous growth in trends is
not uniform for all the NTDs. For example, there has
been a significant decline in trachoma and leprosy
research. Focusing on the granted patent families, a stag-
nation can be observed after 2008, not a decline. Addition-
ally, previously marginalized diseases such as dracunculiasis
were successful in attracting research interest in the last 10
years. However, global patenting trend is in sharp contrast
with the findings on NTDs in this study. In the last 20 years,
the total number of global patenting applications has tripled
[23], but patent application increase on NTDs has not yet
reached this rate. In order to better demonstrate the pro-
portions of patenting activity, the number of patent fam-
ilies, corrected for normalized DALY (2015), was compared
with a few other selected similarly robust social-, health-
and economic impact diseases such as HIV/AIDS, malaria,
cardiovascular diseases, cancers, and lung cancer [14]. The
gap between patenting NTDs and cardiovascular diseases/
cancers is striking; the number of filed patents for cardio-
vascular diseases or cancer is at least 200 times larger than
NTDs. Individual NTDs lag behind lung cancer, malaria or
HIV/AIDS in patenting activities. Background data is pre-
sented in Additional file 3. R&D interests among NTDs is
very uneven. Leishmaniasis, dengue, schistosomiasis and ra-
bies accounted for most of the growth in patenting activ-
ities. An obvious link between disease burden or availability
of treatment (eg. PCT or IDM category) and patenting ac-
tivity could not be identified in this study. This study find-
ing shows that there is a limited attractiveness in this field,
and this is consistent with previous articles on novel drug
and vaccine landscape of NTDs by showing decrease as a
tendency. Cohen et al., found 32 new chemical entities be-
tween 1975 and 1999, while between 2000 and 2009, there
was only 26 newly approved drugs and vaccines for NTDs
[24]. Pedrique et al., reported that most progress towards
reducing the burden of NTDs focus on repurposing or re-
formulating existing drugs [25]. The Bill and Melinda Gates
Foundation which has funded Policy Cures Research to
conduct the last nine annual G-FINDER surveys also found
stagnation in terms of new chemical entities of NTDs [26].
The analysis of this study also showed that the US is
losing its position as a major priority country. This is
consistent with the fact that China now drives global pa-
tent applications beginning with a new record achieved
in 2015 [22]. Diversity between original and current as-
signees such as US Health vs Merck & Co.; Pasteur vs
Vertex Pharma Institute have been found in the patent
database. This is a clear sign of emerging new interested
parties. However, a high number of non-firm assignees
indicates the limited level of industrial maturity in this
field. A higher percentage of firms are assignees resident
in the US in the field of NTDs compared to China.
However, in China, there is a high proportion of patent
families linked to univeristies or individuals which indi-
cates high research activity.
An additional concern could be the high proportion of
expired NTDs patents. Expired patents have limited
strategic value to their assignees. This is because others
cannot be excluded from using the invention(s) disclosed
in the patent. However, information from expired pat-
ents may be relevant in the mitigation of NTDs, and can
be used by non-governmental organizations (NGOs) or
private-public partnerships who are key players to curb-
ing the spread of NTDs [27].
The overall description of information contained in
patent families was through technology fields. The main
technology subdomains with emerging trends are pharma-
ceuticals and biotechnology. Many of the patents retrieved
have strong focus towards medicinal preparations contain-
ing antigens or antibodies.
Based on the method of patent landscape analysis,
patent families of each NTD were identified, merged
and analysed to get overall insights regarding the trends,
topics, and stakeholders in this field. This work could be
a robust basis for future research in order to plan, moni-
tor or justify decisions for R&D policies.
Although, this paper argues that pursuing R&D efforts
in NTDs through the development of new innovations is
important. R&D does not provide answers for several
observed problems within the NTDs. It is important to
pay attention to the broad social factors affecting NTDs;
parallel improvements in hygiene, sanitation and access
to medical care cannot be overlooked. Finding effective
ways for development seems possible through public-
private partnerships or new innovative alliances, estab-
lished on case by case basis. Ways of addressing social
challenges of NTDs may be found by taking good exam-
ples from HIV/AIDS management [28].
It is important to note that there are a number of
methodological limitations in this study. There are limi-
tations to the use of patent data as an indicator of
technological development. This is primarily because
not all inventions meet patentability standards, and
inventors tend to rely on secrecy or other appropriate
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means to protect their inventions. Although, the devel-
oped search criteria facilitated the retrieval of patents of
each NTD, it limited the absolute scope of a patent
search. This simply mean that some patents might have
not been included in the dataset intentionally. This is,
however, a general limitation of all patent landscape ana-
lyses. Additionally, there is usually a time lag of at least
18 months between the first patent filing and the patent
publication; and even longer time is used for granting.
Finally, R&D analysis alone cannot show trends and
future scencarios of research fields. Patent landscape
analyses are quite simple, yet an effective way of plan-
ning and/or monitoring R&D of NTDs.
Conclusion
The filing pattern of patent families reviewed strongly
reveals limited efforts on research and development of
NTDs, whereas it is crucial to intensify research efforts
into NTDs. Involving new players, such as more NGOs
may help to mitigate and reduce the burden of NTDs. In
this work, patent landscape analysis has been presented
as a reliable method that can be adopted for providing
feedback on overall research progress of identified
NTDs. R&D incentives are not sufficient to solve the
problem of inaccessibility of essential medicines in
regions affected by NTDs. Strengthening the health sys-
tems, political and global health efforts will be of
immense benefits to the most affected regions.
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